180 related articles for article (PubMed ID: 37021650)
1. Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.
Yasinskaya Y; Bala S; Waack U; Dixon C; Higgins K; Moore JN; Jjingo CJ; O'Shaughnessy E; Colangelo P; Botgros R; Nambiar S; Angulo D; Dane A; Chiller T; Hodges MR; Sandison T; Hope W; Walsh TJ; Pappas P; Katragkou A; Kovanda L; Rex JH; Marr KA; Ostrosky-Zeichner L; Sekine S; Deshpande M; Shukla SJ; Farley J
Clin Infect Dis; 2023 Aug; 77(3):380-387. PubMed ID: 37021650
[TBL] [Abstract][Full Text] [Related]
2. FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.
O'Shaughnessy E; Yasinskaya Y; Dixon C; Higgins K; Moore J; Reynolds K; Ampel NM; Angulo D; Blair JE; Catanzaro A; Galgiani JN; Garvey E; Johnson R; Larwood DJ; Lewis G; Purdie R; Rex JH; Shubitz LF; Stevens DA; Page SJ; Shukla SJ; Farley JJ; Nambiar S
Clin Infect Dis; 2022 Jun; 74(11):2061-2066. PubMed ID: 34651656
[TBL] [Abstract][Full Text] [Related]
3. FDA Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development.
Jjingo CJ; Bala S; Waack U; Needles M; Bensman TJ; McMaster O; Smith T; Blakely B; Chan IZ; Puthawala K; Dixon C; Kim Y; Lim R; Colangelo P; St Clair C; Nambiar S; Moss RB; Botgros R; Bazaz R; Denning DW; Marr KA; Husain S; Berman L; Christensen DJ; Keywood C; Clayton RG; Walsh TJ; Song HSE; Shukla SJ; Farley JJ
Clin Infect Dis; 2023 Oct; ():. PubMed ID: 37802928
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
5. Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology.
Cornely OA; Hoenigl M; Lass-Flörl C; Chen SC; Kontoyiannis DP; Morrissey CO; Thompson GR;
Mycoses; 2019 Sep; 62(9):716-729. PubMed ID: 31254420
[TBL] [Abstract][Full Text] [Related]
6. Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective.
Lamoth F; Lewis RE; Kontoyiannis DP
Clin Infect Dis; 2022 Aug; 75(3):534-544. PubMed ID: 34986246
[TBL] [Abstract][Full Text] [Related]
7. 2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan.
Kung HC; Huang PY; Chen WT; Ko BS; Chen YC; Chang SC; Chuang YC; ; ; ;
J Microbiol Immunol Infect; 2018 Feb; 51(1):1-17. PubMed ID: 28781150
[TBL] [Abstract][Full Text] [Related]
8. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
9. Patients at high risk of invasive fungal infections: when and how to treat.
Rüping MJ; Vehreschild JJ; Cornely OA
Drugs; 2008; 68(14):1941-62. PubMed ID: 18778118
[TBL] [Abstract][Full Text] [Related]
10. Overcoming clinical challenges in the management of invasive fungal infections in low- and middle-income countries (LMIC).
Chakrabarti A; Patel AK; Soman R; Todi S
Expert Rev Anti Infect Ther; 2023; 21(10):1057-1070. PubMed ID: 37698201
[TBL] [Abstract][Full Text] [Related]
11. An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections.
Mueller SW; Kedzior SK; Miller MA; Reynolds PM; Kiser TH; Krsak M; Molina KC
Expert Opin Pharmacother; 2021 Jul; 22(10):1355-1371. PubMed ID: 33878996
[No Abstract] [Full Text] [Related]
12. Drug development challenges and strategies to address emerging and resistant fungal pathogens.
McCarthy MW; Walsh TJ
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):577-584. PubMed ID: 28480775
[TBL] [Abstract][Full Text] [Related]
13. Management of invasive fungal infections: a role for polyenes.
Chandrasekar P
J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787
[TBL] [Abstract][Full Text] [Related]
14. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).
Lortholary O; Fernández-Ruiz M; Perfect JR
J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA; Gelone SP
Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
[TBL] [Abstract][Full Text] [Related]
16. Innovative therapies for invasive fungal infections in preclinical and clinical development.
Yu Y; Albrecht K; Groll J; Beilhack A
Expert Opin Investig Drugs; 2020 Sep; 29(9):961-971. PubMed ID: 32662681
[TBL] [Abstract][Full Text] [Related]
17. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of antifungal therapies: do we really need it and what are the best practices?
Boyer J; Hoenigl M; Kriegl L
Expert Rev Clin Pharmacol; 2024 Apr; 17(4):309-321. PubMed ID: 38379525
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Clark NM; Grim SA; Lynch JP
Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
[TBL] [Abstract][Full Text] [Related]
20. Nascent Nanoformulations as an Insight into the Limitations of the Conventional Systemic Antifungal Therapies.
Kaur M; Shivgotra R; Bhardwaj N; Saini S; Thakur S; Jain SK
Curr Drug Targets; 2023; 24(2):171-190. PubMed ID: 36443967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
